Conference Coverage

Empagliflozin favorably reshaped left ventricles in HFrEF patients

Publish date: November 15, 2020

 

FROM AHA 2020

mzoler@mdedge.com

Pages

Recommended Reading

When should students resume sports after a COVID-19 diagnosis?
MDedge Cardiology
Novel drug slows progression of diabetic kidney disease
MDedge Cardiology
Updated heart failure measures add newer meds
MDedge Cardiology
MADIT-CRT: Resynchronization linked to fewer heart failure hospitalizations
MDedge Cardiology
Medicare fines half of hospitals for readmitting too many patients
MDedge Cardiology
New return-to-play recommendations for athletes with COVID-19
MDedge Cardiology
No link shown between thyroid dysfunction and heart failure
MDedge Cardiology
GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit
MDedge Cardiology
TIPS-3: Polypill provides meaningful primary cardiovascular prevention
MDedge Cardiology
Intravenous iron reduces HF readmissions: AFFIRM-AHF
MDedge Cardiology